7-117509093-G-T
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM1PM2PP3_Strong
The NM_000492.4(CFTR):c.224G>T(p.Arg75Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000013 in 1,612,264 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R75Q) has been classified as Benign.
Frequency
Consequence
NM_000492.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.224G>T | p.Arg75Leu | missense_variant | 3/27 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.224G>T | p.Arg75Leu | missense_variant | 3/27 | 1 | NM_000492.4 | ENSP00000003084.6 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152176Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.00000797 AC: 2AN: 250966Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135648
GnomAD4 exome AF: 0.0000103 AC: 15AN: 1460088Hom.: 0 Cov.: 29 AF XY: 0.00000963 AC XY: 7AN XY: 726546
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152176Hom.: 0 Cov.: 33 AF XY: 0.0000538 AC XY: 4AN XY: 74340
ClinVar
Submissions by phenotype
Cystic fibrosis Uncertain:3Other:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 02, 2021 | This sequence change replaces arginine with leucine at codon 75 of the CFTR protein (p.Arg75Leu). The arginine residue is moderately conserved and there is a moderate physicochemical difference between arginine and leucine. This variant is present in population databases (rs1800076, ExAC 0.01%). This missense change has been observed in individuals with congenital bilateral absence of the vas deferens (PMID: 7739684, 8556303). ClinVar contains an entry for this variant (Variation ID: 53461). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 24, 2023 | The p.R75L variant (also known as c.224G>T), located in coding exon 3 of the CFTR gene, results from a G to T substitution at nucleotide position 224. The arginine at codon 75 is replaced by leucine, an amino acid with dissimilar properties. The variant has been detected with p.F508del in a man with congenital bilateral absence of the vas deferens (CBAVD) (Mercier B et al. Am J Hum Genet, 1995 Jan;56:272-7; Chillón M et al. N Engl J Med, 1995 Jun;332:1475-80; Steiner B et al. Hum Mutat, 2011 Aug;32:912-20). This alteration was reported in additional individuals with CBAVD or cystic fibrosis; however, it is unknown whether these individuals had a second CFTR alteration (Kanavakis E et al. Clin Genet, 2003 May;63:400-9; Gallati S et al. Reprod Biomed Online, 2009 Nov;19:685-94; Akin Y et al. Andrologia, 2014 Mar;46:198-9). Minigene assay in different cell lines showed that the variant increases skipping of exon 3 (Aissat A et al. Hum Mutat, 2013 Jun;34:873-81). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
not provided, no classification provided | literature only | ClinVar Staff, National Center for Biotechnology Information (NCBI) | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Apr 04, 2022 | - - |
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | May 09, 2023 | The CFTR c.224G>T; p.Arg75Leu variant (rs1800076) is reported in the literature in the compound heterozygous state in individuals affected with congenital absence of the vas deferens (Chillon 1995,Costes 1995, De Braekeleer 1996, Mercier 1996, Steiner 2011). This variant is also reported in ClinVar (Variation ID: 53461), and is only observed on three alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. Computational analyses predict that this variant is deleterious (REVEL: 0.915). Due to limited information, the clinical significance of this variant is uncertain at this time. References: Chillon M et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med. 1995 Jun 1;332(22):1475-80. PMID: 7739684. Costes B et al. Frequent occurrence of the CFTR intron 8 (TG)n 5T allele in men with congenital bilateral absence of the vas deferens. Eur J Hum Genet. 1995;3(5):285-93. PMID: 8556303. De Braekeleer M et al. Mutations in the cystic fibrosis gene in men with congenital bilateral absence of the vas deferens. Mol Hum Reprod. 1996 Sep;2(9):669-77. PMID: 9239681. Mercier B et al. Is congenital bilateral absence of vas deferens a primary form of cystic fibrosis? Analyses of the CFTR gene in 67 patients. Am J Hum Genet. 1995 Jan;56(1):272-7. PMID: 7529962. Steiner B et al. Common CFTR haplotypes and susceptibility to chronic pancreatitis and congenital bilateral absence of the vas deferens. Hum Mutat. 2011 Aug;32(8):912-20. PMID: 21520337. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Nov 29, 2021 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 17, 2024 | Variant summary: CFTR c.224G>T (p.Arg75Leu) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. Consensus agreement among computation tools predict no significant impact on normal splicing. However, further in silico analysis focusing on splicing factor binding sites revealed loss of binding site for SF2/ASF and disruption of two 9G8-binding motifs (Aissat_2013). The same study reporting a mini gene assay demonstrated the variant to result in a 37% increase in exon 3 skipping. The variant allele was found at a frequency of 8e-06 in 250966 control chromosomes (gnomAD). c.224G>T has been reported in the literature in individuals affected with Congenital Bilateral Absence of the Vas Deferens along with DeltaF508 (Mercier_1995, DeBraekeleer_1996, Chillon_1995, Gallati_2009, Steiner_2011) and in one case of Cystic Fibrosis without a second allele reported (Kanavakis_2003). These data indicate that the variant may be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 7529962, 9239681, 7739684, 12752573, 20021716, 21520337, 23420618). ClinVar contains an entry for this variant (Variation ID: 53461). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at